natgillin/translations-raw huggingface dataset:
Den maksimale reduktion i blodtrykket opnås generelt 4- 8 uger, efter behandlingen er påbegyndt og fastholdes gennem langtidsbehandling.
The maximum reduction in blood pressure is generally attained 4 to 8 weeks after the start of treatment and is sustained during long-term therapy.
Dette er bekræftet ved målinger, der blev foretaget på tidspunktet for maksimal effekt og umiddelbart forud for den næste dosis (trough/ peak ratio var over 80% efter dosering af 40 mg og 80 mg telmisartan i alle placebokontrollerede kliniske forsøg).
This is confirmed by trough to peak ratios consistently above 80% seen after doses of 40 and 80 mg of telmisartan in placebo controlled clinical studies.
Der er en tydelig trend mod en dosisafhængighed i forhold til tid til tilbagevenden til baseline for det systoliske blodtryk (SBT).
There is an apparent trend to a dose relationship to a time to 8 recovery of baseline systolic blood pressure (SBP).
8 Hos patienter med hypertension reducerer telmisartan både det systoliske og det diastoliske blodtryk uden at påvirke pulsen.
In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate.
Telmisartans eventuelle positive indvirkning på mortalitet og kardiovaskulær morbiditet er indtil videre ukendt.
Beneficial effects of telmisartan on mortality and cardiovascular morbidity are currently unknown.
50%.
The mean absolute bioavailability for telmisartan is about 50%.
19% (160 mg dosis).
When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC0-∞) of telmisartan varies from approximately 6% (40 mg dose) to approximately 19% (160 mg dose).
Linearitet/ non- linearitet: Den lille reduktion i AUC forventes ikke at forårsage en reduktion i terapeutisk effekt.
The small reduction in AUC is not expected to cause a reduction in the therapeutic efficacy.
Telmisartan er i høj grad bundet til plasmaprotein (> 99, 5%), hovedsagelig til albumin og Alfa I- syreglycoprotein.
Telmisartan is largely bound to plasma protein (> 99.5%), mainly albumin and alpha-1 acid glycoprotein.
500 l.
The mean steady state apparent volume of distribution (Vdss) is approximately 500 l.
Telmisartan er karakteriseret ved en farmakokinetisk bieksponentiel udskillelse med en terminal eliminationshalveringstid på > 20 timer.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of > 20 hours.
Den kumulative udskillelse i urinen er < 1% af dosis.
Cumulative urinary excretion is < 1% of dose.
1000 ml/ min.) sammenlignet med den hepatiske blodgennemstrømning (ca.
Total plasma clearance (Cltot) is high (approximately 1,000 ml/ min) compared with hepatic blood flow (about 1,500 ml/ min).
1500 ml/ min.).
Special Populations
Specielle befolkningsgrupper
Gender effects:
3 og 2 gange højere hos kvinder end hos mænd.
9 Differences in plasma concentrations were observed, with Cmax and AUC being approximately 3- and 2-fold higher, respectively, in females compared to males.
9 Telmisartans farmakokinetikske egenskaber er ikke anderledes hos ældre patienter i forhold til de der er under 65 år.
The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.
Desuden blev der fundet ventrikel- slimhindelæsioner (erosion, ulcus eller inflammation) i rotter og hunde.
Gastric mucosal injury (erosion, ulcers or inflammation) also was noted in rats and dogs.
Disse farmakologisk betingede bivirkninger, som er kendt fra prækliniske forsøg med både ACE- hæmmere og angiotensin II- receptorantagonister, kunne forhindres/ afhjælpes ved peroral salttilførsel.
These pharmacologically- mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation.
Hos begge dyrearter fandt man forøget plasma- reninaktivitet og hypertrofi/ hyperplasi af de renale juxtaglomerulære celler.
In both species, increased plasma renin activity and hypertrophy/ hyperplasia of the renal juxtaglomerular cells were observed.
Disse fund synes ikke at være af signifikant klinisk betydning og anses også for at være klasseeffekter ved ACE- hæmmere og andre angiotensin II- receptorantagonister,.
These changes, also a class effect of angiotensin converting enzyme inhibitors and other angiotensin II receptor antagonists, do not appear to have clinical significance.
Der er ingen tegn på teratogenisitet, men man fandt en potentiel risiko ved telmisartan for den postnatale udvikling af afkommet så som lavere legemsvægt, forsinket åbning af øjnene og højere mortalitet.
There is no evidence of a teratogenic effect, but animal studies indicated some hazardous potential of telmisartan to the postnatal development of the offspring such as lower body weight, delayed eye opening, and higher mortality.
Der var ingen tegn på mutagenicitet eller relevant klasteogen aktivitet ved in vitro- forsøg og ingen tegn på karcinogenicitet i rotter og mus.
There was no evidence of mutagenicity and relevant clastogenic activity in in vitro studies and no evidence of carcinogenicity in rats and mice.
3 år.
10 3 years
Polyamid/ aluminium/ PVC blisterpakning
Aluminium/ aluminium blisters (PA/ PA/ Al/ PVC/ Al).
14 tabletter 28 tabletter 56 tabletter 98 tabletter
Blister with 14, 28, 56, or 98 tablets.
Ingen særlige forhold.
No special requirements.
EU/ 1/ 98/ 091/ 009 (14 tabletter) EU/ 1/ 98/ 091/ 010 (28 tabletter) EU/ 1/ 98/ 091/ 011 (56 tabletter) EU/ 1/ 98/ 091/ 012 (98 tabletter)
EU/ 1/ 98/ 091/ 009 (14 tablets) EU/ 1/ 98/ 091/ 010 (28 tablets) EU/ 1/ 98/ 091/ 011 (56 tablets) EU/ 1/ 98/ 091/ 012 (98 tablets)
16. december 1998 Dato for forlængelse af markedsføringstilladelse:
16 December 1998 Date of last renewal:
Yderligere information om dette lægemiddel er tilgængelig på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http: // www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Hvide aflange tabletter, hvori firmaets logo og koden 51H er præget.
White oblong tablets engraved with the code number '51H 'on one side.
4. 4 og 4. 6)
• Hypersensitivity to the active substance or to any of the excipients (see section 6.1) • Second and third trimester of pregnancy (see sections 4.4 and 4.6)
4. 6) • Obstruktive galdelidelser • Svært nedsat leverfunktion
12 • Lactation (see section 4.6) • Biliary obstructive disorders • Severe hepatic impairment
13 Aorta - og mitralklapstenose, obstruktiv hypertrofisk kardiomyopati:
13 Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:
Kaliumholdige saltsubstitutter, kaliumbesparende diuretika, ACE- hæmmere, angiotensin II- receptorantagonister, non steroide antiinflammatoriske lægemidler (NSAIDs herunder selektive COX- 2- hæmmere), heparin, immunosuppressiva (cyclosporin eller tacrolimus) og trimethoprim.
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti- inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Derimod er kombinationer med ACE- hæmmere eller NSAID mindre risikable, forudsat at de foreskrevne forholdsregler følges.
A combination with ACE inhibitors or NSAIDs, for example, presents a lesser risk provided that precautions for use are strictly followed.
Nedenstående kombinationer frarådes.
14 Concomitant use not recommended
Kaliumbesparende diuretika eller kaliumtilskud:
Potassium sparing diuretics or potassium supplements:
14 Angotensin II- receptorantagonister, såsom telmisartan, mindsker diuretisk fremkaldt kaliumtab.
Angiotensin II receptor antagonists such as telmisartan, attenuate diuretic induced potassium loss.
4. 3 og 4. 4):
15 Pregnancy (see section 4.3 and 4.4):
Meget almindelig (≥ 1/ 10); almindelig (≥ 1/ 100 til < 1/ 10); ikke almindelig (≥ 1/ 1. 000 til < 1/ 100); sjælden (≥ 1/ 10. 000 til < 1/ 1. 000); meget sjælden (< 1/ 10. 000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥ 1/ 10); common (≥ 1/ 100 to < 1/ 10); uncommon (≥ 1/ 1,000 to < 1/ 100); rare (≥ 1/ 10,000 to < 1/ 1,000); very rare (< 1/ 10,000), not known (cannot be estimated from the available data).
Anæmi, thrombocytopeni Eosinofili
Anaemia, thrombocytopenia Eosinophilia
16 Metabolisme og ernæring
16
Brystsmerter, Influenzalignende symptomer Manglende virkning af lægemidlet
Chest pain Influenza-like illness Drug ineffective
17 Laboratorieundesøgelser
17 Investigations
18 Hos patienter med hypertension reducerer telmisartan både det systoliske og det diastoliske blodtryk uden at påvirke pulsen.
18 In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate.
1500 ml/ min.).
Total plasma clearance (Cltot) is high (approximately 1,000 ml/ min) compared with hepatic blood flow (about 1,500 ml/ min).
Specielle befolkningsgrupper
Special Populations
Kønsforskel i plasmakoncentrationer:
Gender effects:
3 og 2 gange højere hos kvinder end hos mænd.
Differences in plasma concentrations were observed, with Cmax and AUC being approximately 3- and 2-fold higher, respectively, in females compared to males.
19 Telmisartans farmakokinetikske egenskaber er ikke anderledes hos ældre patienter i forhold til de der er under 65 år.
19 The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.
20 6. 4 Særlige opbevaringsforhold
20 This medicinal product does not require any special storage conditions.
Polyamid/ aluminium/ PVC- blisterpakning
6.5 Nature and contents of container
14 tabletter 28 tabletter 56 tabletter 98 tabletter
Aluminium/ aluminium blisters (PA/ PA/ Al/ PVC/ Al). One blister contains 7 tablets.
28 x 1 tablet Polyamid/ aluminium/ PVC- perforerede enkelt dosis
Blister with 14, 28, 56, or 98 tablets or perforated unit dose blisters with 28 x 1 tablets.
EU/ 1/ 98/ 091/ 001 (14 tablets) EU/ 1/ 98/ 091/ 002 (28 tablets) EU/ 1/ 98/ 091/ 003 (56 tablets) EU/ 1/ 98/ 091/ 004 (98 tablets) EU/ 1/ 98/ 091/ 013 (28 x 1 tablets)
EU/ 1/ 98/ 091/ 001 (14 tablets) EU/ 1/ 98/ 091/ 002 (28 tablets) EU/ 1/ 98/ 091/ 003 (56 tablets) EU/ 1/ 98/ 091/ 004 (98 tablets) EU/ 1/ 98/ 091/ 013 (28 x 1 tablets)
Yderlige information om dette lægemiddel er tilgængelig på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http: // www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Hvide aflange tabletter, hvori firmaets logo og koden 52H er præget.
White oblong tablets engraved with the code number '52H 'on one side.
Børn Kinzalmono bør ikke anvendes til børn og unge under 18 år på grund af utilstrækkelig dokumentation for sikkerhed og virkning.
Kinzalmono is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
4. 6) • Obstruktive galdelidelser • Svært nedsat leverfunktion
22 • Lactation (see section 4.6) • Biliary obstructive disorders • Severe hepatic impairment
23 Aorta - og mitralklapstenose, obstruktiv hypertrofisk kardiomyopati:
23 Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:
4. 8).
As with others drugs acting on the renin-angiotensin-aldosterone-system, telmisartan may provoke hyperkalaemia (see section 4.4).
Nedenstående kombinationer frarådes.
A combination with ACE inhibitors or NSAIDs, for example, presents a lesser risk provided that precautions for use are strictly followed.
24 Angotensin II- receptorantagonister, såsom telmisartan, mindsker diuretisk fremkaldt kaliumtab.
24 Concomitant use not recommended
4. 3 og 4. 4):
25 Pregnancy (see section 4.3 and 4.4):
26 Metabolisme og ernæring
26
27 Laboratorieundesøgelser
27 Investigations
28 Hos patienter med hypertension reducerer telmisartan både det systoliske og det diastoliske blodtryk uden at påvirke pulsen.
28 In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate.
Ældre patienter:
29 Elderly patients:
29 Telmisartans farmakokinetikske egenskaber er ikke anderledes hos ældre patienter i forhold til de der er under 65 år.
The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.
Der er ingen tegn på teratogenisitet, men man fandt en potentiel risiko ved telmisartan for den postnatale udvikling af afkommet så som lavere legemsvægt, forsinket åbning af øjnene og højere mortalitet.
There is no evidence of a teratogenic effect but animal studies indicated some hazardous potential of telmisartan to the postnatal development of the offspring such as lower body weight, delayed eye opening, and higher mortality.
30 6. 4 Særlige opbevaringsforhold
30 This medicinal product does not require any special storage conditions.
6. 5 Emballage, type og pakningsstørrelser
6.5 Nature and contents of container
Polyamid/ aluminium/ PVC- blisterpakning
Aluminium/ aluminium blisters (PA/ PA/ Al/ PVC/ Al).
14 tabletter 28 tabletter 56 tabletter 98 tabletter
One blister contains 7 tablets.
28 x 1 tablet Polyamid/ aluminium/ PVC- perforerede enkelt dosis
Blister with 14, 28, 56 or 98 tablets or perforated unit dose blisters with 28 x 1 tablets.
EU/ 1/ 98/ 091/ 005 (14 tablets) EU/ 1/ 98/ 091/ 006 (28 tablets) EU/ 1/ 98/ 091/ 007 (56 tablets) EU/ 1/ 98/ 091/ 008 (98 tablets) EU/ 1/ 98/ 091/ 014 (28 x 1 tablets)
EU/ 1/ 98/ 091/ 005 (14 tablets) EU/ 1/ 98/ 091/ 006 (28 tablets) EU/ 1/ 98/ 091/ 007 (56 tablets) EU/ 1/ 98/ 091/ 008 (98 tablets) EU/ 1/ 98/ 091/ 014 (28 x 1 tablets)
INDEHAVERE AF VIRKSOMHEDSGODKENDELSER ANSVARLIGE FOR BATCHFRIGIVELSE
32 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
PSUR Indehaver af markedsføringstilladelsen vil forsat en gang om året indsende PSUR, medmindre andet specificeres af CHMP.
PSURs The MAH will continue to submit yearly PSURs, unless otherwise specified by the CHMP.
Indeholder sorbitol (E420) Se flere oplysninger i indlægssedlen
Read the package leaflet for further information.
Ingen krav til opbevaringstemperatur Opbevares i originalpakning for at beskytte mod fugt
Store in the original package in order to protect from moisture.
37 MINDSTEKRAV TIL OPLYSNINGER PÅ BLISTERKORT ELLER BLISTERSTRIPS
37 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Bayer HealthCareAG (Logo)
Bayer HealthCare AG (Logo)
SÆRLIGE OPBEVARINGSBETINGELSER
39 Store in the original package in order to protect from moisture.
40 MINDSTEKRAV TIL OPLYSNINGER PÅ BLISTERKORT ELLER BLISTERSTRIPS
40 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Unit dose- blister (28 x 1 tablet) og andre blisterkort bortset fra 7 styk
Unit dose blister (28 x 1 tablets pack)
SÆRLIGE OPBEVARINGSBETINGELSER
43 Store in the original package in order to protect from moisture.
Kinzalmono 20 mg tabletter Telmisartan
INFORMATION FOR THE USER Kinzalmono 20 mg tablets Telmisartan
Læs hele denne indlægsseddel grundigt, inden du begynder at tage medicinen.
Read all of this leaflet carefully before you start taking this medicine. • Keep this leaflet.
- Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller du får bivirkninger, som
It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Virkning og anvendelse 2.
What Kinzalmono is and what it is used for 2.
Det skal du vide, før du begynder at tage Kinzalmono 3.
Before you take Kinzalmono 3.
Sådan skal du tage Kinzalmono 4.
How to take Kinzalmono 4.
Opbevaring 6.
How to store Kinzalmono 6.
VIRKNING OG ANVENDELSE
WHAT KINZALMONO IS AND WHAT IT IS USED FOR
Telmisartan er en angiotensin II - receptorantagonist.
Kinzalmono belongs to a class of medicines known as angiotensin II receptor antagonists.
Når blodkarrene snævrer ind, stiger blodtrykket.
Angiotensin II is a substance produced in your body which causes your blood vessels to narrow, thus increasing your blood pressure.
Kinzalmono- tabletter bruges til behandling af essentiel hypertension (forhøjet blodtryk). ’ Essentiel ’ betyder, at der ikke er nogen anden sygdom, der er årsag til, at blodtrykket er forhøjet.
Kinzalmono is used to treat essential hypertension (high blood pressure). ‘ Essential’ means that the high blood pressure is not caused by any other condition.
Hvis forhøjet blodtryk ikke behandles, kan der ske skader på blodkarrene i flere organer, som kan føre til hjerteanfald, hjerte - eller nyresvigt, slagtilfælde eller blindhed.
High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness.
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE KINZALMONO
BEFORE YOU TAKE KINZALMONO
• hvis du er overfølsom (allergisk) over for telmisartan eller et af de øvrige indholdsstoffer (se under punkt 6) • hvis du er i de sidste 6 måneder af graviditeten (se afsnit Graviditet og amning) • hvis du ammer • hvis du har alvorlige leverproblemer, såsom kolestase eller galdevejsobstruktion (problem med udskillelse af galde fra leveren eller fra galdeblæren) eller anden alvorlig leversygdom
• if you are allergic (hypersensitive) to telmisartan or any other ingredients included in Kinzalmono tablets (see section Further information for a list of other ingredients). • during the last six months of pregnancy (see section Pregnancy and breast-feeding). • if you are breast-feeding. • if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the liver and gall bladder) or any other severe liver disease.
48 Vær ekstra forsigtig med at tage Kinzalmono
Take special care with Kinzalmono
Fortæl det til lægen, hvis du har eller har haft nogen af nedenstående sygdomme eller tilstande: • Nyresygdom eller du har fået en nyre transplantation • Nedsat blodtilstrømning til en eller begge nyrer / nyrearteriestenose) • Leversygdom • Hjerteproblemer • Aldosteronnisme (vand eller saltophobning i kroppen samtidig med ubalance i mineral sammensætningen) • For lavt blodtryk (hypotension), som kan forekomme, hvis du er dehydreret (overdrevent tab af kropsvæske) eller er i saltunderskud efter anvendelse af vanddrivende medicin, er på saltfattig kost, har diarré eller ved opkastning. • Har et højt kaliumindhold i blodet (de hyppigste årsager til dette er sukkersyge, nedsat nyrefunktion, alder over 70 år og kaliumtilskud, eller medicin, der påvirker blodets indhold af kalium) • Diabetes
48 • Renal artery stenosis (narrowing of the blood vessels to one or both kidneys). • Liver disease. • Heart trouble. • Raised aldosterone levels (water and salt retention in the body along with imbalance of various blood minerals). • Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy ('water tablets'), low-salt diet, diarrhoea, or vomiting. • Elevated potassium levels in your blood. • Diabetes.
Kinzalmono kan ikke anbefales til gravide.
You must tell your doctor if you think that you are (or might become) pregnant.
Hvis Kinzalmono tages mere end 3 måneder henne i graviditeten, kan det forårsage alvorlige fosterskader (se afsnit Graviditet og amning).
Kinzalmono is not recommended in early pregnancy and may cause serious harm to your baby after 3 months of pregnancy (see section Pregnancy and breast-feeding).
Kinzalmono er, som alle andre angiotensin II- receptorantagonister, mindre effektiv til at sænke blodtrykket hos sorte mennesker.
As with all other angiotensin II receptor antagonists, Kinzalmono may be less effective in lowering the blood pressure in black patients.
Fortæl det altid til lægen eller apoteket, hvis du bruger anden medicin eller har gjort det for nylig.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Dette gælder også håndkøbsmedicin.
Your doctor may need to change the dose of these other medications or take other precautions.
Hvis du sammen med Kinzalmono tager visse andre typer medicin, kan det være nødvendigt at ændre dosis.
In some cases you may have to stop taking one of the medicines.
Muligvis vil det være nødvendigt at stoppe brugen af anden medicin, specielt hvis der er noget af følgende:
This applies especially to the medicines listed below taken at the same time with Kinzalmono:
• Medicin, som indeholder lithium til behandling af depression. • Medicin, som kan forhøje blodets indhold af kalium, såsom kaliumholdige saltsubstitutter, kaliumbesparende medicin (visse typer diuretika eller vanddrivende tabletter) ACE- hæmmere, angiotensin II- recptorantagonister, non steroid antiinflammatoriske medicintyper (NSAID´er som aspirin og ibuprofen), heparin, lægemidler der undertrykker immunsystemet (som cyclosporin og tacrolimus) og antibiobica indeholdende trimethoprim. • Vanddrivende medicin (diuretica) i høje doser kan føre til overdrevent tab af kropsvæske og for lavt blodtryk (hypotension).
• Lithium containing medicines to treat some types of depression. • Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain'water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e. g. aspirin or ibuprofen), heparin, immunosuppressives (e. g. cyclosporin or tacrolimus), and the antibiotic trimethoprim. • Diuretics ('water tablets'), especially if taken in high doses together with Kinzalmono, may lead to excessive loss of body water and low blood pressure (hypotension).
Den blodtrykssænkende virkning med Kinzalmono kan, ligesom ved anden blodtrykssænkende medicin, blive mindre, hvis du samtidig tager medicin mod gigt og lette smerter (non- steroid antiinflammatorisk medicin (NSAID) såsom aspirin eller ibuprofen) eller kortikosteroider.
As with other blood pressure lowering medicines, the effect of Kinzalmono may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e. g. aspirin or ibuprofen) or corticosteroids.
Kinzalmono kan øge den blodtryksnedsættende virkning af andre blodtryksnedsættende lægemidler.
Kinzalmono may increase the blood pressure lowering effect of other medicines used to treat high blood pressure.
Brug af Kinzalmono sammen med mad og drikke
Taking Kinzalmono with food and drink
Tabletterne kan både tages sammen med mad og alene.
You can take Kinzalmono with or without food.
49 Graviditet og amning
Pregnancy and breast-feeding
Spørg din læge eller apotek til råds, før du tager nogen form for medicin.
You must tell your doctor if you think that you are (or might become) pregnant.
Normalt vil lægen anbefale en anden type medicin, da Kinzalmono ikke kan anbefales til gravide.
Usually, your doctor will advise you to take another medicine instead of Kinzalmono, as Kinzalmono is not recommended in early pregnancy, and may cause serious harm to your baby if it is used after 3 months of pregnancy.
Kinzalmono kan forårsage alvorlig fosterskade, hvis det tages mere end 3 måneder henne i graviditeten.
Appropriate antihypertensive drug must usually replace Kinzalmono before starting a pregnancy.
Passende blodtrykssænkende medicin bør erstatte Kinzalmono før en graviditet.
Kinzalmono should not be used during the second and third trimester of pregnancy.
Normalt vil lægen anbefale, at du straks stopper med at tage Kinzalmono, hvis du bliver gravid.
49 Your doctor will normally advise you to stop taking Kinzalmono as soon as you know you are pregnant.
Kontakt lægen, hvis du bliver gravid og er i behandling med Kinzalmono.
If you become pregnant during therapy with Kinzalmono, please inform and see your doctor without delay.
Du bør ikke tage Kinzalmono, hvis du ammer.
You must not take Kinzalmono if you are breast-feeding.